Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.34 |
| ▸ | PAICS | P22234 | 3/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26783757 | 0.94 | PAICS (0.32) | TLR8TLR7PAICSTLR9NAMPT | |
| SCHEMBL29314867 | 0.91 | PAICS (0.33) | TLR8TLR7PAICSNAMPT | |
| SCHEMBL29314637 | 0.88 | TLR7 (0.35) | TLR8TLR7NAMPTCSNK1DCSNK1E | |
| SCHEMBL29314642 | 0.87 | TLR8 (0.36) | TLR8TLR7NAMPTIRAK4ABL1 | |
| SCHEMBL29314635 | 0.87 | TLR8 (0.33) | TLR8TLR7NAMPT | |
| SCHEMBL29314648 | 0.86 | TLR8 (0.34) | TLR8TLR7NAMPT | |
| SCHEMBL29314640 | 0.86 | SMN1; SMN2 (0.35) | TLR8TLR7NAMPTABL1BCR | |
| SCHEMBL29314715 | 0.86 | MAPT (0.36) | TLR8TLR7NAMPTABL1BCR | |
| SCHEMBL29314633 | 0.86 | HIF1A (0.36) | TLR8TLR7NAMPTABL1BCR | |
| SCHEMBL23037710 | 0.86 | TLR7 (0.40) | TLR8TLR7NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR8 210/4885TLR7 236/4885PAICS 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.